{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:55:27Z","timestamp":1793933727488,"version":"4.8.0"},"reference-count":115,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This clinical consensus statement, developed by the Heart Failure Association of the European Society of Cardiology, offers a detailed review of the non-specific management of transthyretin amyloid cardiomyopathy (ATTR-CM). This progressive and often fatal condition is increasingly recognized as a major contributor to heart failure. This document provides advice on symptom management and enhancing quality of life, with a focus on volume management, neurohormonal modulation, and tailored use of diuretics and other supportive therapies that address the distinct pathophysiology of ATTR-CM. It also explores advanced treatment modalities such as heart transplantation and mechanical circulatory support, which play crucial roles in managing advanced stages of the disease. Furthermore, it addresses the management of aortic stenosis in the context of ATTR-CM, advising transcatheter aortic valve replacement as the preferred treatment for these patients. The advice provided in this document relies primarily on expert opinion and retrospective studies due to a notable lack of randomized clinical trials, which underscores a critical research gap and the pressing need for evidence-based treatment protocols.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaf710","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:50:31Z","timestamp":1756813831000},"page":"22-36","source":"Crossref","is-referenced-by-count":37,"title":["Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, GUARD-HEART ERN , Manuel de Falla, 2, Madrid 28222 ,","place":["Spain"]},{"name":"CIBER Cardiovascular, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , C. de Melchor Fern\u00e1ndez Almagro, 3, Fuencarral-El Pardo, 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonzalez-Lopez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, GUARD-HEART ERN , Manuel de Falla, 2, Madrid 28222 ,","place":["Spain"]},{"name":"CIBER Cardiovascular, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J","family":"Anderson","sequence":"additional","affiliation":[{"name":"Cardiology Clinical Academic Group, St George's Hospital, London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Tuscan Regional Amyloidosis Centre, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3848","authenticated-orcid":false,"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"Referral Center for Cardiac Amyloidosis and Department of Cardiology, APHP CHU Henri Mondor Cr\u00e9teil and R\u00e9seau Amylose and Fili\u00e8re Cardiogen, GUARD-HEART ERN , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, UCL, Division of Medicine, Royal Free Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Gonzalez-Costello","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Bellvitge, Hospitalet de Llobregat , Barcelona ,","place":["Spain"]},{"name":"Bio-Heart, Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-2612","authenticated-orcid":false,"given":"Ruxandra","family":"Jurcut","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy \u2018Carol Davila\u2019 , Bucharest ,","place":["Romania"]},{"name":"Expert Center for Rare Cardiovascular Diseases, Emergency Institute for Cardiovascular Diseases \u2018Prof.dr.C.C.Iliescu\u2019, GUARD-HEART ERN , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[{"name":"Toulouse University, HealthAge University Hospital Institute , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-4413","authenticated-orcid":false,"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Experimental Cardiology University Medical Center Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-3131","authenticated-orcid":false,"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[{"name":"Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), GUARD-HEART ERN , Trieste ,","place":["Italy"]},{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Perlini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Emergency Medicine and Amyloidosis Research and Treatment Center, IRCCS Policlinico San Matteo Foundation, Universit\u00e0 degli Studi , Pavia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-197X","authenticated-orcid":false,"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"CIBER Cardiovascular, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"l'Institut del Cor. Hospital Universitari Germans Trias i Pujol , 08916 Badalona ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2026080910070141400_ehaf710-B1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"2026080910070141400_ehaf710-B2","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080910070141400_ehaf710-B3","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez","year":"2025","journal-title":"Eur Heart J"},{"key":"2026080910070141400_ehaf710-B4","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"2026080910070141400_ehaf710-B5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.medcli.2020.06.064","article-title":"Transthyretin amyloid cardiomyopathy","volume":"156","author":"Garcia-Pavia","year":"2021","journal-title":"Med Clin (Barc)"},{"key":"2026080910070141400_ehaf710-B6","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080910070141400_ehaf710-B7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.rec.2024.07.005","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study","volume":"78","author":"Garc\u00eda-Pav\u00eda","year":"2025","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026080910070141400_ehaf710-B8","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026080910070141400_ehaf710-B9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ejhf.3186","article-title":"Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: results of the Amylo-VIP-HF study","volume":"26","author":"Tubben","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080910070141400_ehaf710-B10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/13506129.2019.1625322","article-title":"Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders","volume":"26","author":"L\u00f3pez-Sainz","year":"2019","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/13506129.2024.2398446","article-title":"International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction","volume":"31","author":"Yun","year":"2024","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B12","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080910070141400_ehaf710-B13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion\u2014a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080910070141400_ehaf710-B14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080910070141400_ehaf710-B15","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","article-title":"Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial","volume":"29","author":"Ter Maaten","year":"2023","journal-title":"Nat Med"},{"key":"2026080910070141400_ehaf710-B16","doi-asserted-by":"publisher","first-page":"e011105","DOI":"10.1161\/CIRCHEARTFAILURE.123.011105","article-title":"Protocolized natriuresis-guided decongestion improves diuretic response: the multicenter ENACT-HF study","volume":"17","author":"Dauw","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026080910070141400_ehaf710-B17","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080910070141400_ehaf710-B18","doi-asserted-by":"publisher","first-page":"1367790","DOI":"10.3389\/fphar.2024.1367790","article-title":"Safety of midodrine in patients with heart failure with reduced ejection fraction: a retrospective cohort study","volume":"15","author":"Wu","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026080910070141400_ehaf710-B19","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080910070141400_ehaf710-B20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial","volume":"44","author":"Trull\u00e0s","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080910070141400_ehaf710-B21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ahj.2020.12.009","article-title":"Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic","volume":"233","author":"Vaishnav","year":"2021","journal-title":"Am Heart J"},{"key":"2026080910070141400_ehaf710-B22","doi-asserted-by":"publisher","first-page":"e011796","DOI":"10.1161\/CIRCHEARTFAILURE.124.011796","article-title":"Guideline-directed medical therapy for heart failure in transthyretin amyloid cardiomyopathy","volume":"18","author":"Schwarting","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026080910070141400_ehaf710-B23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/13506129.2021.1966624","article-title":"Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure","volume":"28","author":"Vergaro","year":"2021","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: transthyretin cardiac amyloid study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026080910070141400_ehaf710-B25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","article-title":"Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?","volume":"24","author":"Aus dem Siepen","year":"2017","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B26","doi-asserted-by":"publisher","first-page":"e022859","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026080910070141400_ehaf710-B27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.mayocp.2021.08.006","article-title":"Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy","volume":"97","author":"Barge-Caballero","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2026080910070141400_ehaf710-B28","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080910070141400_ehaf710-B29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/13506129.2023.2232520","article-title":"Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy","volume":"32","author":"Cabrera-Romero","year":"2025","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026080910070141400_ehaf710-B31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.repc.2022.12.008","article-title":"Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fraction","volume":"42","author":"Negreira-Caama\u00f1o","year":"2023","journal-title":"Rev Port Cardiol"},{"key":"2026080910070141400_ehaf710-B32","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080910070141400_ehaf710-B33","doi-asserted-by":"publisher","first-page":"101405","DOI":"10.1016\/j.jacadv.2024.101405","article-title":"Sodium-glucose cotransporter 2 inhibitor use and outcomes in transthyretin amyloid cardiomyopathy","volume":"3","author":"Jaiswal","year":"2024","journal-title":"JACC Adv"},{"key":"2026080910070141400_ehaf710-B34","doi-asserted-by":"publisher","first-page":"e14392","DOI":"10.1111\/eci.14392","article-title":"Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis","volume":"55","author":"Karakasis","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"2026080910070141400_ehaf710-B35","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.healun.2024.05.010","article-title":"International Society for heart and lung transplantation guidelines for the evaluation and care of cardiac transplant candidates-2024","volume":"43","author":"Peled","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"2026080910070141400_ehaf710-B36","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.recesp.2021.07.007","article-title":"Characterization of hereditary transthyretin cardiac amyloidosis in Spain","volume":"75","author":"\u00c1lvarez Rubio","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026080910070141400_ehaf710-B37","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080910070141400_ehaf710-B38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/13506129.2022.2142110","article-title":"Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain","volume":"30","author":"de Frutos","year":"2023","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.rec.2023.11.001","article-title":"Review of the allocation criteria for heart transplant in Spain in 2023. SEC-Heart Failure Association\/ONT\/SECCE consensus document","volume":"77","author":"Gonz\u00e1lez-Costello","year":"2024","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026080910070141400_ehaf710-B40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"2026080910070141400_ehaf710-B41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2022.10.012","article-title":"How to identify cardiac amyloidosis patients who might benefit from cardiac transplantation","volume":"11","author":"Ambardekar","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026080910070141400_ehaf710-B42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/13506129.2020.1784134","article-title":"TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients","volume":"27","author":"Moshe-Lilie","year":"2020","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B43","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.healun.2023.01.001","article-title":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation: the eurotransplant experience","volume":"42","author":"Kraus","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"2026080910070141400_ehaf710-B44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2026080910070141400_ehaf710-B45","doi-asserted-by":"publisher","first-page":"e943498","DOI":"10.12659\/AOT.943498","article-title":"Use of LCP-tacrolimus (LCPT) in kidney transplantation: a Delphi consensus survey of expert clinicians","volume":"29","author":"Wiseman","year":"2024","journal-title":"Ann Transplant"},{"key":"2026080910070141400_ehaf710-B46","doi-asserted-by":"publisher","first-page":"1075806","DOI":"10.3389\/fcvm.2022.1075806","article-title":"Cardiac transplantation in transthyretin amyloid cardiomyopathy: outcomes from three decades of tertiary center experience","volume":"9","author":"Razvi","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026080910070141400_ehaf710-B47","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.healun.2022.12.004","article-title":"The 2023 International Society for heart and lung transplantation guidelines for mechanical circulatory support: a 10- year update","volume":"42","author":"Saeed","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"2026080910070141400_ehaf710-B48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.healun.2013.01.987","article-title":"Left ventricular device implantation for advanced cardiac amyloidosis","volume":"32","author":"Swiecicki","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"2026080910070141400_ehaf710-B49","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/ehf2.13422","article-title":"A case series of cardiac amyloidosis patients supported by continuous-flow left ventricular assist device","volume":"8","author":"Randhawa","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026080910070141400_ehaf710-B50","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10741-022-10288-w","article-title":"Left ventricular assist device in cardiac amyloidosis: friend or foe?","volume":"28","author":"Sciaccaluga","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2026080910070141400_ehaf710-B51","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.healun.2015.03.012","article-title":"Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease","volume":"34","author":"Grupper","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"2026080910070141400_ehaf710-B52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/ejcts\/ezz098","article-title":"2019 EACTS expert consensus on long-term mechanical circulatory support","volume":"56","author":"Potapov","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026080910070141400_ehaf710-B53","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1002\/ehf2.14039","article-title":"Two-year outcome of ventricular assist device via a modified left atrium to aorta approach in cardiac amyloidosis","volume":"9","author":"Lim","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026080910070141400_ehaf710-B54","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026080910070141400_ehaf710-B55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B56","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080910070141400_ehaf710-B57","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"2026080910070141400_ehaf710-B58","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"key":"2026080910070141400_ehaf710-B59","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B60","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080910070141400_ehaf710-B61","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080910070141400_ehaf710-B62","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080910070141400_ehaf710-B63","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080910070141400_ehaf710-B64","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jacc.2024.04.066","article-title":"Safety of direct current cardioversion without routine transesophageal echocardiography in patients with cardiac amyloidosis","volume":"84","author":"Itzhaki Ben Zadok","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080910070141400_ehaf710-B65","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"2026080910070141400_ehaf710-B66","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"key":"2026080910070141400_ehaf710-B67","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080910070141400_ehaf710-B68","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080910070141400_ehaf710-B69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2021","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B70","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.recesp.2022.07.011","article-title":"Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study","volume":"76","author":"Amat-Santos","year":"2023","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026080910070141400_ehaf710-B71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/13506129.2017.1323735","article-title":"A-V block as presentation of cardiac amyloid: prominent infiltration of conduction tissue revealed by endomyocardial biopsy","volume":"24","author":"Frustaci","year":"2017","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B72","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026080910070141400_ehaf710-B73","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026080910070141400_ehaf710-B74","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/S0002-9440(10)64469-0","article-title":"Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro","volume":"161","author":"Sousa","year":"2002","journal-title":"Am J Pathol"},{"key":"2026080910070141400_ehaf710-B75","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026080910070141400_ehaf710-B76","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"2026080910070141400_ehaf710-B77","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/heartjnl-2022-322315","article-title":"Predictors and outcomes of pacemaker implantation in patients with cardiac amyloidosis","volume":"110","author":"Saturi","year":"2023","journal-title":"Heart"},{"key":"2026080910070141400_ehaf710-B78","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080910070141400_ehaf710-B79","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jacep.2020.04.020","article-title":"Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis","volume":"6","author":"Rehorn","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080910070141400_ehaf710-B80","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Heart Rhythm"},{"key":"2026080910070141400_ehaf710-B81","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026080910070141400_ehaf710-B82","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.rec.2021.08.016","article-title":"Initial experience with left bundle branch area pacing in patients with transthyretin cardiac amyloidosis","volume":"75","author":"Berm\u00fadez-Jim\u00e9nez","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026080910070141400_ehaf710-B83","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1093\/ehjci\/jead331","article-title":"Impact of left bundle branch area pacing-optimized cardiac resynchronized therapy for transthyretin cardiac amyloidosis","volume":"25","author":"Sudo","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080910070141400_ehaf710-B84","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/pace.14894","article-title":"Feasibility and safety of left bundle branch area pacing in cardiac amyloidosis. A single center experience","volume":"47","author":"Pham-Trung","year":"2024","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026080910070141400_ehaf710-B85","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/13506129.2024.2414295","article-title":"Incidence and predictors of sudden death in patients with cardiac amyloidosis","volume":"31","author":"de Frutos","year":"2024","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B86","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"2026080910070141400_ehaf710-B87","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/pace.14023","article-title":"Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis","volume":"43","author":"Donnellan","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026080910070141400_ehaf710-B88","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijcard.2021.11.057","article-title":"Mode of death and outcomes of implantable cardioverter defibrillators in transthyretin amyloid cardiomyopathy","volume":"349","author":"Dale","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026080910070141400_ehaf710-B89","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026080910070141400_ehaf710-B90","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/pace.14458","article-title":"Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis","volume":"45","author":"Brown","year":"2022","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026080910070141400_ehaf710-B91","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080910070141400_ehaf710-B92","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","volume":"41","author":"Scully","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080910070141400_ehaf710-B93","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080910070141400_ehaf710-B94","doi-asserted-by":"publisher","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","article-title":"Plasminogen activation triggers transthyretin amyloidogenesis in vitro","volume":"293","author":"Mangione","year":"2018","journal-title":"J Biol Chem"},{"key":"2026080910070141400_ehaf710-B95","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.carrev.2022.07.011","article-title":"Aortic stenosis and cardiac amyloidosis: PARTNERs in crime?","volume":"43","author":"Argiro\u2019","year":"2022","journal-title":"Cardiovasc Revasc Med"},{"key":"2026080910070141400_ehaf710-B96","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ejhf.1974","article-title":"Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis","volume":"23","author":"Rosenblum","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080910070141400_ehaf710-B97","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/heartjnl-2021-319922","article-title":"Impact of afterload and infiltration on coexisting aortic stenosis and transthyretin amyloidosis","volume":"108","author":"Patel","year":"2022","journal-title":"Heart"},{"key":"2026080910070141400_ehaf710-B98","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026080910070141400_ehaf710-B99","doi-asserted-by":"publisher","first-page":"e005066","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080910070141400_ehaf710-B100","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.carrev.2022.04.027","article-title":"Clinical outcome of TAVR vs. SAVR in patients with cardiac amyloidosis","volume":"43","author":"Khan","year":"2022","journal-title":"Cardiovasc Revasc Med"},{"key":"2026080910070141400_ehaf710-B101","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.hlc.2023.09.019","article-title":"Clinical outcomes of aortic stenosis in amyloidosis: a United States national cohort study","volume":"33","author":"Mir","year":"2024","journal-title":"Heart Lung Circ"},{"key":"2026080910070141400_ehaf710-B102","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1002\/ehf2.13876","article-title":"Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta-analysis","volume":"9","author":"Cannata","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026080910070141400_ehaf710-B103","doi-asserted-by":"publisher","first-page":"e014115","DOI":"10.1161\/CIRCIMAGING.122.014115","article-title":"Reverse remodeling following valve replacement in coexisting aortic stenosis and transthyretin cardiac amyloidosis","volume":"15","author":"Nitsche","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080910070141400_ehaf710-B104","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41572-024-00589-9","article-title":"Chronic kidney disease","volume":"11","author":"Romagnani","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026080910070141400_ehaf710-B105","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.3390\/jcm10153415","article-title":"Frailty in wild-type transthyretin cardiac amyloidosis: the tip of the iceberg","volume":"10","author":"Broussier","year":"2021","journal-title":"J Clin Med"},{"key":"2026080910070141400_ehaf710-B106","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13506129.2019.1698417","article-title":"Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype","volume":"27","author":"Driggin","year":"2020","journal-title":"Amyloid"},{"key":"2026080910070141400_ehaf710-B107","doi-asserted-by":"publisher","first-page":"101123","DOI":"10.1016\/j.jacadv.2024.101123","article-title":"Comprehensive geriatric assessment to optimize the management of older patients with transthyretin cardiac amyloidosis","volume":"3","author":"Fumagalli","year":"2024","journal-title":"JACC Adv"},{"key":"2026080910070141400_ehaf710-B108","doi-asserted-by":"publisher","first-page":"1238843","DOI":"10.3389\/fcvm.2023.1238843","article-title":"Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study","volume":"10","author":"Ponti","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026080910070141400_ehaf710-B109","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","article-title":"Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries","volume":"143","author":"Johansson","year":"2021","journal-title":"Circulation"},{"key":"2026080910070141400_ehaf710-B110","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080910070141400_ehaf710-B111","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026080910070141400_ehaf710-B112","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026080910070141400_ehaf710-B113","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/ehf2.14350","article-title":"Health-related quality of life among transthyretin amyloid cardiomyopathy patients","volume":"10","author":"Eldhagen","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026080910070141400_ehaf710-B114","doi-asserted-by":"publisher","first-page":"e073130","DOI":"10.1136\/bmjopen-2023-073130","article-title":"Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals","volume":"13","author":"Obici","year":"2023","journal-title":"BMJ open"},{"key":"2026080910070141400_ehaf710-B115","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/1\/22\/64537688\/ehaf710.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/1\/22\/64537688\/ehaf710.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T14:07:12Z","timestamp":1786284432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/1\/22\/8276835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2026,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf710","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,1]]},"published":{"date-parts":[[2025,10,7]]}}}